NEWS

• KyDo has been awarded with the 2026 MATWIN price for the best drug-based innovation project in oncology.
• KyDo’s lead program consists of novel covalent-allosteric inhibitors with the potential to become best-in-class oncology drugs.

May 27th, 2026, Dortmund, Germany – KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company committed to developing novel covalent-allosteric small molecule inhibitors with the potential to become best-in-class oncology drugs, announced today the reception of the 2026 MATWIN award for the best drug-based innovation project in oncology. The selection is made once a year by the MATWIN board comprising oncology experts from 9 different pharmaceutical companies...

• KyDo secures €4.45 million Seed Funding to develop KyDo’s covalent allosteric drug discovery platform and to advance its frontrunner inhibitors towards IND-enabling studies.
• The financing round is led by I&I Bio, with a significant investment from KHAN-II, and investments from VORNvc and TU capital.
• KyDo´s lead program consists of novel covalent-allosteric inhibitors with potential to become first-in-class oncology drugs.

September 16th, 2025, Dortmund, Germany – KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company committed to developing novel covalent-allosteric small molecule inhibitors with the potential to become first-in-class oncology drugs, announced today the closing of its seed financing round of €4.45 million. The financing will support the development of KyDo’s frontrunner compounds for the treatment of challenging cancer variants...